Biocure Technology Inc. (BICTF)
USD 0.63
(0.0%)
USD 0.63
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.05 Million CAD | 160.88% |
| 2022 | 403.4 Thousand USD | -71.69% |
| 2021 | 1.42 Million CAD | -40.2% |
| 2020 | 2.38 Million CAD | -32.09% |
| 2019 | 3.5 Million CAD | -45.62% |
| 2018 | 6.45 Million CAD | 359.35% |
| 2017 | 1.4 Million CAD | 43.29% |
| 2016 | 980.5 Thousand CAD | 86296.8% |
| 2015 | 1134.89 CAD | -98.62% |
| 2014 | 82.32 Thousand CAD | -2.66% |
| 2013 | 84.57 Thousand CAD | -32.74% |
| 2012 | 125.74 Thousand CAD | 17.49% |
| 2011 | 107.02 Thousand CAD | -28.49% |
| 2010 | 149.67 Thousand CAD | 67.58% |
| 2009 | 89.31 Thousand CAD | 97.77% |
| 2008 | 45.16 Thousand CAD | 650.66% |
| 2007 | 6016.00 CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 46.24 Thousand USD | 28.04% |
| 2024 Q1 | 49.42 Thousand USD | -46.98% |
| 2023 Q4 | 93.21 Thousand USD | 130.85% |
| 2023 Q1 | 59.81 Thousand USD | -79.3% |
| 2023 Q2 | 75.8 Thousand USD | 26.74% |
| 2023 FY | 1.49 Million CAD | 270.47% |
| 2023 Q3 | 40.37 Thousand USD | -46.74% |
| 2022 Q2 | 195.83 Thousand CAD | -17.28% |
| 2022 Q4 | 288.94 Thousand USD | 76.14% |
| 2022 Q3 | 164.04 Thousand CAD | -16.23% |
| 2022 FY | 403.4 Thousand USD | -71.69% |
| 2022 Q1 | 236.76 Thousand CAD | 153.3% |
| 2021 Q1 | 1.07 Million CAD | -29.7% |
| 2021 Q3 | 1.14 Million CAD | -9.49% |
| 2021 Q2 | 1.27 Million CAD | 18.32% |
| 2021 Q4 | -444.24 Thousand CAD | -138.65% |
| 2021 FY | 1.42 Million CAD | -40.2% |
| 2020 Q4 | 1.52 Million CAD | 287.86% |
| 2020 Q2 | 436.63 Thousand CAD | -28.17% |
| 2020 Q3 | 393.67 Thousand CAD | -9.84% |
| 2020 Q1 | 607.83 Thousand CAD | -60.2% |
| 2020 FY | 2.38 Million CAD | -32.09% |
| 2019 Q3 | 696.19 Thousand CAD | -62.05% |
| 2019 FY | 3.5 Million CAD | -45.62% |
| 2019 Q2 | 1.83 Million CAD | 240.75% |
| 2019 Q1 | 538.36 Thousand CAD | -48.24% |
| 2019 Q4 | 1.52 Million CAD | 119.35% |
| 2018 FY | 6.45 Million CAD | 359.35% |
| 2018 Q4 | 1.04 Million CAD | 88.29% |
| 2018 Q3 | 552.41 Thousand CAD | -85.65% |
| 2018 Q2 | 3.84 Million CAD | 280.33% |
| 2018 Q1 | 1.01 Million CAD | 538.8% |
| 2017 FY | 1.4 Million CAD | 43.29% |
| 2017 Q1 | 300.35 CAD | -77.25% |
| 2017 Q3 | 26.59 Thousand CAD | 23.12% |
| 2017 Q2 | 21.6 Thousand CAD | 7092.01% |
| 2017 Q4 | 158.43 Thousand CAD | 495.71% |
| 2016 Q1 | 10.25 Thousand CAD | -69.7% |
| 2016 FY | 980.5 Thousand CAD | 86296.8% |
| 2016 Q3 | 38.78 Thousand CAD | 170.32% |
| 2016 Q4 | 1320.24 CAD | -96.6% |
| 2016 Q2 | 14.34 Thousand CAD | 39.95% |
| 2015 Q3 | 15.55 Thousand CAD | -1.76% |
| 2015 Q4 | 33.83 Thousand CAD | 117.53% |
| 2015 Q2 | 15.83 Thousand CAD | -22.35% |
| 2015 FY | 1134.89 CAD | -98.62% |
| 2015 Q1 | 20.38 Thousand CAD | 24.34% |
| 2014 Q1 | 21.94 Thousand CAD | 21.3% |
| 2014 Q2 | 21.45 Thousand CAD | -2.25% |
| 2014 Q3 | 24.08 Thousand CAD | 12.28% |
| 2014 Q4 | 16.39 Thousand CAD | -31.92% |
| 2014 FY | 82.32 Thousand CAD | -2.66% |
| 2013 FY | 84.57 Thousand CAD | -32.74% |
| 2013 Q4 | 18.09 Thousand CAD | -28.49% |
| 2013 Q2 | 19.24 Thousand CAD | -58.02% |
| 2013 Q3 | 25.29 Thousand CAD | 31.46% |
| 2013 Q1 | 45.84 Thousand CAD | 92.95% |
| 2012 Q4 | 23.75 Thousand CAD | 48.78% |
| 2012 Q3 | 15.96 Thousand CAD | -59.41% |
| 2012 Q1 | 22.37 Thousand CAD | -20.37% |
| 2012 Q2 | 39.34 Thousand CAD | 75.82% |
| 2012 FY | 125.74 Thousand CAD | 17.49% |
| 2011 Q3 | 13.31 Thousand CAD | -69.2% |
| 2011 Q1 | -75.19 Thousand CAD | -145.39% |
| 2011 Q2 | 43.23 Thousand CAD | 157.49% |
| 2011 FY | 107.02 Thousand CAD | -28.49% |
| 2011 Q4 | 28.1 Thousand CAD | 111.03% |
| 2010 Q1 | 8339.00 CAD | 43.85% |
| 2010 Q2 | 14.08 Thousand CAD | 68.89% |
| 2010 Q3 | 41.55 Thousand CAD | 195.05% |
| 2010 Q4 | 165.66 Thousand CAD | 298.67% |
| 2010 FY | 149.67 Thousand CAD | 67.58% |
| 2009 Q2 | 4334.00 CAD | -87.08% |
| 2009 Q3 | 50.45 Thousand CAD | 1064.07% |
| 2009 Q4 | 5797.00 CAD | -88.51% |
| 2009 FY | 89.31 Thousand CAD | 97.77% |
| 2009 Q1 | 33.54 Thousand CAD | 3302.03% |
| 2008 Q1 | 2499.00 CAD | -92.2% |
| 2008 Q3 | 8883.00 CAD | 406.44% |
| 2008 Q4 | 986.00 CAD | -88.9% |
| 2008 FY | 45.16 Thousand CAD | 650.66% |
| 2008 Q2 | 1754.00 CAD | -29.81% |
| 2007 Q4 | 32.02 Thousand CAD | 0.0% |
| 2007 FY | 6016.00 CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.787% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 78.601% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.771% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 96.439% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 97.175% |
| Mesoblast Limited | 5.9 Million USD | 82.169% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 29.929% |
| Genus plc | 147.7 Million USD | 99.287% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 88.013% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 21.554% |
| Marizyme, Inc. | 19.23 Million USD | 94.53% |
| ContraFect Corporation | 56.88 Million USD | 98.15% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 87.38% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 76.129% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 28.832% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 63.913% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 62.285% |
| MultiCell Technologies, Inc. | 567.42 USD | -185369.493% |
| Accustem Sciences Inc. | 3.74 Million USD | 71.909% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.776% |
| EV Biologics, Inc. | 531.96 Thousand USD | -97.832% |
| Q BioMed Inc. | 3.43 Million USD | 69.377% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 95.742% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -170.144% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 59.947% |
| Biomind Labs Inc. | 994.18 Thousand USD | -5.855% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 99.533% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 84.335% |
| Skye Bioscience, Inc. | 13.54 Million USD | 92.232% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 48.631% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 4309.564% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 79.128% |
| IMV Inc. | 37.7 Million USD | 97.209% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 93.427% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 42.652% |
| GB Sciences, Inc. | 1.42 Million USD | 25.915% |
| Alpha Cognition Inc. | 9.7 Million USD | 89.157% |
| HST Global, Inc. | 140.9 Thousand USD | -646.869% |
| CSL Limited | 3.44 Billion USD | 99.969% |
| Halberd Corporation | 74.84 Thousand USD | -1306.15% |
| Enzolytics Inc. | 2.17 Million USD | 51.714% |
| Resverlogix Corp. | 12.71 Million USD | 91.721% |
| Affymax, Inc. | 39.38 Million USD | 97.328% |
| SYBLEU INC | 160.87 Thousand USD | -554.163% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 71.173% |
| argenx SE | 1.53 Billion USD | 99.931% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 98.168% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -0.804% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 33.366% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 69.093% |
| AVAX Technologies, Inc. | 7.31 Million USD | 85.604% |
| Zenith Capital Corp. | 8.94 Million USD | 88.232% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.872% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -5940.933% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 57.138% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -513.607% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.941% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 40.194% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | 46.634% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 43.552% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 90.316% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 45.214% |
| BioStem Technologies, Inc. | 22.97 Million USD | 95.419% |
| ONE Bio Corp. | 6.44 Million USD | 83.668% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -479.878% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | 21.195% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 6.447% |
| Agentix Corp. | 1.37 Million USD | 23.281% |
| LadRx Corporation | 3.81 Million USD | 72.391% |
| Cell Source, Inc. | 4.32 Million USD | 75.669% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -153.296% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -13.956% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -13.956% |
| NovAccess Global Inc. | 2.46 Million USD | 57.337% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 56.24% |
| Itoco Inc. | 919.14 Thousand USD | -14.497% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 75.17% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 5.953% |
| Kadimastem Ltd | 2.41 Million USD | 56.334% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -302.096% |
| CytoDyn Inc. | 18.05 Million USD | 94.172% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -4081.298% |
| Mobile Lads Corp. | 554.54 Thousand USD | -89.775% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -378.19% |
| Qrons Inc. | 643.67 Thousand USD | -63.497% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 25.877% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | 52.805% |
| Rebus Holdings, Inc. | 664 Thousand USD | -58.493% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 42.059% |
| International Stem Cell Corporation | 5.27 Million USD | 80.034% |
| Bioxytran, Inc. | 3.82 Million USD | 72.452% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -1899.147% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -5073.234% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 97.098% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 34.957% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -43.02% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 66.172% |
| Neutra Corp. | 243.82 Thousand USD | -331.624% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 93.972% |
| PureTech Health plc | 144.59 Million USD | 99.272% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 94.864% |
| IXICO plc | 4.7 Million USD | 77.642% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 88.037% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.106% |
| CSL Limited | 3.89 Billion USD | 99.973% |
| Cellectis S.A. | 97.32 Million USD | 98.919% |